Segment reporting (Tables)

6 Months Ended

Jan. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2015
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,725			—			—			—		$	14,725
Product revenues		—		$	7,723			—			—			7,723
Royalty and license fee income		—			644			—			—			644
		14,725			8,367			—			—			23,092
Operating expenses:
Cost of clinical laboratory services		9,246			—			—			—			9,246
Cost of product revenues		—			3,818			—			—			3,818
Research and development		—			635		$	199			—			834
Selling, general and administrative		5,089			2,704			—		$	1,877			9,670
Provision for uncollectible accounts receivable		658			(57	)		—			—			601
Legal fee expense		41			(53	)		—			2,816			2,804
Total operating expenses		15,034			7,047			199			4,693			26,973
Operating income (loss)		(309	)		1,320			(199	)		(4,693	)		(3,881	)
Other income (expense)
Interest		(12	)		5			—			(42	)		(49	)
Other		4			(29	)		—			8			(17	)
Foreign exchange loss		—			(259	)		—			—			(259	)
Income (loss) before income taxes	$	(317	)	$	1,037		$	(199	)	$	(4,727	)	$	(4,206	)
Depreciation and amortization included above	$	357		$	555		$	1		$	22		$	935
Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—		$	1			—			—			1
Selling, general and administrative		12			3			—		$	87			102
Total	$	14		$	4			—		$	87		$	105
Capital expenditures	$	338		$	51		$	—		$	—		$	389

Three months ended January 31, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,848			—			—			—		$	13,848
Product revenues		—		$	8,054			—			—			8,054
Royalty and license fee income		—			1,026			—			—			1,026
		13,848			9,080			—			—			22,928
Operating expenses:
Cost of clinical laboratory services		9,292			—			—			—			9,292
Cost of product revenues		—			3,865			—			—			3,865
Research and development		3			543		$	286			—			832
Selling, general and administrative		4,981			3,318			—		$	1,785			10,084
Provision for uncollectible accounts receivable		920			(8	)		—			—			912
Legal fee expense		142			15			—			1,339			1,496
Total operating expenses		15,338			7,733			286			3,124			26,481
Operating income (loss)		(1,490	)		1,347			(286	)		(3,124	)		(3,553	)
Other income (expense)
Interest		(11	)		3			—			(44	)		(52	)
Other		9			(6	)		—			12			15
Foreign exchange gain		—			20			—			—			20
Income (loss) before income taxes	$	(1,492	)	$	1,364		$	(286	)	$	(3,156	)	$	(3,570	)
Depreciation and amortization included above	$	355		$	621		$	2		$	24		$	1,002
Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	5			—		$	93			107
Total	$	11		$	5			—		$	93		$	109
Capital expenditures	$	103		$	7		$	—		$	—		$	110

Six months ended January 31, 2015
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	30,547			—			—			—		$	30,547
Product revenues		—		$	15,725			—			—			15,725
Royalty and license fee income		—			1,644			—			—			1,644
		30,547			17,369			—			—			47,916
Operating expenses:
Cost of clinical laboratory services		19,376			—			—			—			19,376
Cost of product revenues		—			7,513			—			—			7,513
Research and development		—			1,183		$	442			—			1,625
Selling, general and administrative		10,157			5,853			—		$	3,945			19,955
Provision for uncollectible accounts receivable		1,189			(47	)		—			—			1,142
Legal		131			(51	)		—			5,190			5,270
Total operating expenses		30,853			14,451			442			9,135			54,881
Operating income (loss)		(306	)		2,918			(442	)		(9,135	)		(6,965	)
Other income (expense)
Interest		(39	)		7			—			(86	)		(118	)
Other		6			(35	)		—			31			2
Foreign exchange gain		—			(731	)		—			—			(731	)
Income (loss) before income taxes	$	(339	)	$	2,159		$	(442	)	$	(9,190	)	$	(7,812	)
Depreciation and amortization included above	$	714		$	1,113		$	2		$	44		$	1,873
Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	2			—			—			2
Selling, general and administrative		21			3			—		$	174			198
Total	$	24		$	5			—		$	174		$	203
Capital expenditures	$	589		$	64		$	—		$	—		$	653

Six months ended January 31, 2014
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	28,707			—		—			—		$	28,707
Product revenues		—		$	15,717		—			—			15,717
Royalty and license fee income		—			2,637		—			—			2,637
		28,707			18,354		—			—			47,061
Operating expenses:
Cost of clinical laboratory services		19,001			—		—			—			19,001
Cost of product revenues		—			7,712		—			—			7,712
Research and development		14			1,069	$	566			—			1,649
Selling, general and administrative		10,031			6,813		—		$	3,768			20,612
Provision for uncollectible accounts receivable		1,764			20		—			—			1,784
Legal		290			37		—			2,550			2,877
Total operating expenses		31,100			15,651		566			6,318			53,635
Operating income (loss)		(2,393	)		2,703		(566	)		(6,318	)		(6,574	)
Other income (expense)
Interest		(22	)		8		—			(100)			(114	)
Other		27			21		—			28			76
Foreign exchange gain		—			317		—			—			317
Income (loss) before income taxes	$	(2,388	)	$	3,049	$	(566	)	$	(6,390	)	$	(6,295	)
Depreciation and amortization included above	$	710		$	1,262	$	6		$	49		$	2,027
Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—		—			—		$	4
Research and development		—		$	1		—			—			1
Selling, general and administrative		19			9		—		$	179			207
Total	$	23		$	10		—		$	179		$	212
Capital expenditures	$	362		$	82	$	—		$	—		$	444